Bavituximab: Difference between revisions
Johnfravolda (talk | contribs) added link to article mentioning 3G4 |
Johnfravolda (talk | contribs) mNo edit summary |
||
| Line 29: | Line 29: | ||
}} |
}} |
||
'''Bavituximab''' is a [[Chimera (protein)|chimeric]] anti-phosphatidylserine [[monoclonal antibody]] [[analog]] which some researchers hypothesise may help in the treatment of some [[cancer]]s and [[viral infections]]. |
'''Bavituximab'''<ref>http://www.ama-assn.org/ama1/pub/upload/mm/365/bavituximab.pdf Statement on a nonproprietary name adopted by the USAN council</ref> is a [[Chimera (protein)|chimeric]] anti-phosphatidylserine [[monoclonal antibody]] [[analog]] which some researchers hypothesise may help in the treatment of some [[cancer]]s and [[viral infections]]. |
||
Additional [[functional analog|analog]]s in the class include [[3G4]]<ref>http://www.accessmylibrary.com/coms2/summary_0286-5071158_ITM Pharma company completes humanization of 3G4 antibody.</ref>, [[2aG4]], [[9d2]] and [[Hu3g4]]. |
Additional [[functional analog|analog]]s in the class include [[3G4]]<ref>http://www.accessmylibrary.com/coms2/summary_0286-5071158_ITM Pharma company completes humanization of 3G4 antibody.</ref>, [[2aG4]], [[9d2]] and [[Hu3g4]]. |
||
Revision as of 06:07, 11 August 2009
 | This article needs attention from an expert on the subject. Please add a reason or a talk parameter to this template to explain the issue with the article. (May 2009) |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Immunoglobulin G1, anti-(phosphatidylserine) (human-mouse monoclonal ch3G4 heavy chain), disulfide with human-mouse monoclonal ch3G4 κ-chain, dimer |
| Target | phosphatidylserine, |
| Clinical data | |
| Routes of administration | Infusion |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 30 Hrs |
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C6446H9946N1702O2042S42 |
| Molar mass | 145.3 kDa g·mol−1 |
Bavituximab[1] is a chimeric anti-phosphatidylserine monoclonal antibody analog which some researchers hypothesise may help in the treatment of some cancers and viral infections.
Additional analogs in the class include 3G4[2], 2aG4, 9d2 and Hu3g4.
Mechanism
Bavituximab binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress.
It binds to various aminophospholipids and is dependent on interaction with plasma protein beta2-glycoprotein 1 to mediate binding.
These target aminophospholipids, usually residing only on the inner leaflet of the plasma membrane of cells are purportedly only exposed in virally infected, damaged or malignant cells.
The antibody's binding to phospholipids, alerts the body’s immune system to attack the tumor endothelial cells, thrombosing the tumor's vascular network and/or attacking free floating virally infected and metastatic cells while potentially minimizing side effects in healthy tissues.
Clinical trials
Phase 1B clinical trials have started to test bavituximab against HIV and hepatitis C viral infections.[3]
Phase I and II clinical trials are also in progress for various types of cancer.[4] Promising preliminary results have been reported from a Phase II trial of bavituximab used with docetaxel against advanced breast cancer.[5]
References
- ^ http://www.ama-assn.org/ama1/pub/upload/mm/365/bavituximab.pdf Statement on a nonproprietary name adopted by the USAN council
- ^ http://www.accessmylibrary.com/coms2/summary_0286-5071158_ITM Pharma company completes humanization of 3G4 antibody.
- ^ http://clinicaltrials.gov/ct2/show/NCT00503347 "Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus"
- ^ http://oralcancernews.org/wp/2009/07/peregrine-completes-patient-enrollment-in-bavituximab-trial/
- ^ http://www.biocetera.com/inthenews.php?id=119426
Further reading
- Soares M, Syed S, Barbero G, Thorpe PE (2007). "Antibody-mediated targeting of "inside-out" anionic phospholipids in viral disease". J Immunol. 178: 47.21.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Nature Medicine, V14, p1357.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |